GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Qualigen Therapeutics Inc (NAS:QLGN) » Definitions » Gross Margin %

Qualigen Therapeutics (Qualigen Therapeutics) Gross Margin % : 0.00% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Qualigen Therapeutics Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Qualigen Therapeutics's Gross Profit for the three months ended in Dec. 2023 was $0.00 Mil. Qualigen Therapeutics's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, Qualigen Therapeutics's Gross Margin % for the quarter that ended in Dec. 2023 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for Qualigen Therapeutics's Gross Margin % or its related term are showing as below:

QLGN' s Gross Margin % Range Over the Past 10 Years
Min: 23.36   Med: 25.9   Max: 29.44
Current: 29.44


During the past 4 years, the highest Gross Margin % of Qualigen Therapeutics was 29.44%. The lowest was 23.36%. And the median was 25.90%.

QLGN's Gross Margin % is ranked worse than
78.73% of 743 companies
in the Biotechnology industry
Industry Median: 59.4 vs QLGN: 29.44

Qualigen Therapeutics had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Qualigen Therapeutics was 0.00% per year.


Qualigen Therapeutics Gross Margin % Historical Data

The historical data trend for Qualigen Therapeutics's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qualigen Therapeutics Gross Margin % Chart

Qualigen Therapeutics Annual Data
Trend Mar20 Dec21 Dec22 Dec23
Gross Margin %
28.43 23.36 - -

Qualigen Therapeutics Quarterly Data
Jun19 Sep19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 21.28 37.49 - -

Competitive Comparison of Qualigen Therapeutics's Gross Margin %

For the Biotechnology subindustry, Qualigen Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Qualigen Therapeutics's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Qualigen Therapeutics's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Qualigen Therapeutics's Gross Margin % falls into.



Qualigen Therapeutics Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Qualigen Therapeutics's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

Qualigen Therapeutics's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Qualigen Therapeutics  (NAS:QLGN) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Qualigen Therapeutics had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Qualigen Therapeutics Gross Margin % Related Terms

Thank you for viewing the detailed overview of Qualigen Therapeutics's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Qualigen Therapeutics (Qualigen Therapeutics) Business Description

Traded in Other Exchanges
Address
2042 Corte del Nogal, Suite B, Carlsbad, CA, USA, 92011
Qualigen Therapeutics Inc is a biotechnology company focused on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases using nanoparticle coating technology. It is a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug designation, while also commercializing diagnostics. The Company has viewed its operations and managed its business in one segment operating mainly within the United States and Israel.
Executives
Michael S. Poirier director, officer: Chairman, President and CEO 2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 92011
Amy S. Broidrick director 1440 VALLE GRANDE, ESCONDIDO CA 92025
Kurt H Kruger director 100 FOXBOROUGH BLVD, SUITE 240, FOXBOROUGH MA 02035
Tariq Arshad officer: SVP/Chief Medical Officer 2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 92011
Christopher L. Lotz officer: Vice President of Finance, CFO 2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 90211
Emery Sidney W Jr director C/O QUALIGEN THERAPEUTICS, INC., 2042 CORTE DEL NOGAL, CARLSBAD CA 92011
Richard A. David director 2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 92011
Wajdi Abdul-ahad officer: VP, R&D, CSO 2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 92011
Shishir K. Sinha officer: VP of Operations 2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 92011
Sekisui Diagnostics, Llc 10 percent owner 1 WALL STREET, BURLINGTON MA 01803
Matthew E Korenberg director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Noah Doyle director C/O RITTER PHARMACEUTICALS INC., 1801 CENTURY PARK EAST, SUITE 1820, LOS ANGELES CA 90096
John W Beck officer: Chief Financial Officer C/O RITTER PHARMACEUTICALS, INC., 1880 CENTURY PARK EAST, SUITE 1000, LOS ANGELES CA 90067
Jeffrey S Benjamin officer: VP of Finance 3885 CRESTWOOD PARKWAY, SUITE 550, DULUTH GA 30096
William M. Merino director C/O RITTER PHARMACEUTICALS INC., 1880 CENTURY PARK EAST, SUITE 1000, LOS ANGELES CA 90067

Qualigen Therapeutics (Qualigen Therapeutics) Headlines

From GuruFocus

Qualigen Therapeutics, Inc. Announces 1-for-10 Reverse Stock Split

By Value_Insider Value_Insider 11-22-2022